Position in NVO
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$242,768
-$801,961 QoQ
Shares Held
5,064
-82.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#955
of 1,348 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Rakuten Securities, Inc. holds $3,655,819 across 14 Drug Manufacturers - General names. NVO ranks #4 (6.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,505 | $1,805,142 | |
| 2 | PFE |
Pfizer Inc
|
37,692 | $907,623 | |
| 3 | JNJ |
Johnson & Johnson
|
2,241 | $569,146 | |
| 4 | NVO |
Novo Nordisk A S
This page
|
5,064 | $242,768 | |
| 5 | ABBV |
AbbVie Inc.
|
233 | $58,632 | |
| 6 | MRK |
Merck & Co., Inc.
|
214 | $27,499 | |
| 7 | AMGN |
Amgen Inc
|
40 | $14,484 | |
| 8 | NVS |
Novartis AG
|
65 | $10,186 |
All Filings in NVO
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $242,768 | 5,064 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $1,044,729 | 28,428 | Shares | Defined | 2026-05-01 | |
| 2025-12-31 | $623,381 | 12,252 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $549,073 | 9,895 | Shares | Defined | 2025-10-28 | |
| 2025-06-30 | $356,833 | 5,170 | Shares | Defined | 2025-08-15 | |
| 2025-03-31 | $199,917 | 2,879 | Shares | Defined | 2025-04-18 | |
| 2024-12-31 | $163,696 | 1,903 | Shares | Defined | 2025-02-10 | |
| 2024-09-30 | $893,501 | 7,504 | Shares | Defined | 2024-11-05 | |
| 2024-06-30 | $1,105,093 | 7,742 | Shares | Defined | 2024-07-31 | |
| 2024-03-31 | $1,158,938 | 9,026 | Shares | Defined | 2024-05-01 | |
| 2023-12-31 | $163,554 | 1,581 | Shares | Defined | 2024-01-31 | |
| No filing history on record for this holder in this stock. | ||||||